It’s a real honor for ExcitePCR to be included in Questale’s list of ‘major players’ in the Point-of-Care/Point-of-Need healthcare diagnostics marketplace, said Lyle Probst, President and CEO of ExcitePCR.
PLEASANTON, Calif. (PRWEB)
December 14, 2017
For the first time, ExcitePCR has been recognized as a “major player” in the Point-of-Care/Point-of-Need (POC/PON) healthcare diagnostics marketplace.
According to Questale (a market research firm based in San Francisco, California), ExcitePCR is one of fewer than 20 companies named in its recently published research report under the category of Infectious Diseases Testing. The Questale report — Global POC Molecular Diagnostics Market Size, Status and Forecast 2022 — was published November 21, 2017.
“It’s a real honor for ExcitePCR to be included in Questale’s list of ‘major players’ in the Point-of-Care/Point-of-Need healthcare diagnostics marketplace,” said Lyle Probst, President and CEO of ExcitePCR. “Through our predecessor company, we have been an active participant in identifying and measuring airborne pathogens like anthrax for over 10 years. With the recent advancements we’ve made to our FireflyDX™ technologies, we are looking forward to bringing our first PCR-based testing and diagnostics systems to market next year.”
ExcitePCR’s first commercial product — the FireflyDX-Portable™ — is designed for use in several multi-billion-dollar industries (including medical testing and diagnostics), markets where molecular diagnostics are critical to ensure rapid safety and treatment protocols. Unfortunately, today’s existing solutions for accurately identifying potential pathogens and bio-threats, especially in-the-field at the…